Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 73 to 75 of 75 entries
Sorted by: Best Match Show Resources per page
Is there something else besides the proapoptotic AVPI-segment in the Smac/DIABLO protein?.

Boletin medico del Hospital Infantil de Mexico

Victoria-Acosta G, Martínez-Archundia M, Moreno-Vargas L, Meléndez-Zajgla J, Martínez-Ruiz GU.
PMID: 29421280
Bol Med Hosp Infant Mex. 2016 Nov - Dec;73(6):365-371. doi: 10.1016/j.bmhimx.2016.10.004. Epub 2016 Nov 30.

In mammals, apoptosis is the main mechanism to eliminate unwanted cells, securing tissue homeostasis and consequently maintaining the health in the organism. Classically, apoptosis culminates with the activation of caspases, which are enzymes that display cysteine protease activity to...

Cite
Victoria-Acosta G, Martínez-Archundia M, Moreno-Vargas L, et al. Is there something else besides the proapoptotic AVPI-segment in the Smac/DIABLO protein?. Bol Med Hosp Infant Mex. 2016;73(6):365-371doi: 10.1016/j.bmhimx.2016.10.004.
Victoria-Acosta, G., Martínez-Archundia, M., Moreno-Vargas, L., Meléndez-Zajgla, J., & Martínez-Ruiz, G. U. (2016). Is there something else besides the proapoptotic AVPI-segment in the Smac/DIABLO protein?. Boletin medico del Hospital Infantil de Mexico, 73(6), 365-371. https://doi.org/10.1016/j.bmhimx.2016.10.004
Victoria-Acosta, Georgina, et al. "Is there something else besides the proapoptotic AVPI-segment in the Smac/DIABLO protein?." Boletin medico del Hospital Infantil de Mexico vol. 73,6 (2016): 365-371. doi: https://doi.org/10.1016/j.bmhimx.2016.10.004
Victoria-Acosta G, Martínez-Archundia M, Moreno-Vargas L, Meléndez-Zajgla J, Martínez-Ruiz GU. Is there something else besides the proapoptotic AVPI-segment in the Smac/DIABLO protein?. Bol Med Hosp Infant Mex. 2016 Nov - Dec;73(6):365-371. doi: 10.1016/j.bmhimx.2016.10.004. Epub 2016 Nov 30. PMID: 29421280.
Copy Download .nbib Format: NLM
Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer.

Clinical and translational science

Gomez-Roca C, Even C, Le Tourneau C, Basté N, Delord JP, Sarini J, Vergez S, Temam S, Hoffmann C, Rochaix P, Borcoman E, Gavillet B, Rouits E, Ménétrey A, Brichory F, Purcea D, Vuagniaux G, Zanna C.
PMID: 33742767
Clin Transl Sci. 2022 Jan;15(1):55-62. doi: 10.1111/cts.13002. Epub 2021 Nov 11.

Inhibitor of apoptosis proteins (IAPs) regulate apoptosis and modulate NF-κB signaling thereby driving expression of genes involved in immune/inflammatory responses. The orally available IAP antagonist Debio 1143 has potential to enhance tumor response to chemoradiotherapy and/or immunotherapy. Patients with...

Cite
Gomez-Roca C, Even C, Le Tourneau C, et al. Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer. Clin Transl Sci. 2021;15(1):55-62doi: 10.1111/cts.13002.
Gomez-Roca, C., Even, C., Le Tourneau, C., Basté, N., Delord, J. P., Sarini, J., Vergez, S., Temam, S., Hoffmann, C., Rochaix, P., Borcoman, E., Gavillet, B., Rouits, E., Ménétrey, A., Brichory, F., Purcea, D., Vuagniaux, G., & Zanna, C. (2022). Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer. Clinical and translational science, 15(1), 55-62. https://doi.org/10.1111/cts.13002
Gomez-Roca, Carlos, et al. "Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer." Clinical and translational science vol. 15,1 (2022): 55-62. doi: https://doi.org/10.1111/cts.13002
Gomez-Roca C, Even C, Le Tourneau C, Basté N, Delord JP, Sarini J, Vergez S, Temam S, Hoffmann C, Rochaix P, Borcoman E, Gavillet B, Rouits E, Ménétrey A, Brichory F, Purcea D, Vuagniaux G, Zanna C. Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer. Clin Transl Sci. 2022 Jan;15(1):55-62. doi: 10.1111/cts.13002. Epub 2021 Nov 11. PMID: 33742767; PMCID: PMC8742634.
Copy Download .nbib Format: NLM
Mitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells.

Oncology reports

Horibe S, Ishikawa K, Nakada K, Wake M, Takeda N, Tanaka T, Kawauchi S, Sasaki N, Rikitake Y.
PMID: 34935060
Oncol Rep. 2022 Feb;47(2). doi: 10.3892/or.2021.8243. Epub 2021 Dec 22.

The efficacy of cisplatin (CDDP) has been demonstrated in the treatment of various cancers as monotherapy and combination therapy with immunotherapy. However, acquired CDDP resistance is a major obstacle to successful treatment. In the present study, the mechanisms underlying...

Cite
Horibe S, Ishikawa K, Nakada K, et al. Mitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells. Oncol Rep. 2021;47(2)doi: 10.3892/or.2021.8243.
Horibe, S., Ishikawa, K., Nakada, K., Wake, M., Takeda, N., Tanaka, T., Kawauchi, S., Sasaki, N., & Rikitake, Y. (2022). Mitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells. Oncology reports, 47(2), . https://doi.org/10.3892/or.2021.8243
Horibe, Sayo, et al. "Mitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells." Oncology reports vol. 47,2 (2022). doi: https://doi.org/10.3892/or.2021.8243
Horibe S, Ishikawa K, Nakada K, Wake M, Takeda N, Tanaka T, Kawauchi S, Sasaki N, Rikitake Y. Mitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells. Oncol Rep. 2022 Feb;47(2). doi: 10.3892/or.2021.8243. Epub 2021 Dec 22. PMID: 34935060; PMCID: PMC8717125.
Copy Download .nbib Format: NLM
Showing 73 to 75 of 75 entries